#3-07E. Distinct Paths to Fibrosis: The Molecular Divide in Scleroderma (Arthritis Rheumatol, 2024)

How do we explain the distinct clinical trajectories of localized versus systemic scleroderma at a cellular level? This episode explores a pivotal study comparing the transcriptomic landscapes of these phenotypically distinct conditions. Using single-cell RNA sequencing on skin biopsies, the researchers reveal that localized scleroderma is primarily driven by tertiary lymphoid structures and T follicular helper cells promoting local inflammation. In sharp contrast, systemic sclerosis (SSc) is characterized by a distinct fibroblast subpopulation expressing high levels of CREB3L1. Crucially, the study identifies this transcription factor, CREB3L1, as a master regulator driving systemic fibrosis in both skin and lungs, highlighting it as a novel therapeutic target. However, critical appraisal is necessary; the single-cell analysis was limited to only three patients per group, and the influence of concurrent cyclophosphamide therapy in SSc subjects may confound immune profiling results. For clinicians, this mechanistic divergence supports a shift toward precision medicine, suggesting that localized disease requires targeted anti-inflammatory strategies, whereas SSc may benefit more from specific blockade of the CREB3L1 fibrotic pathway.

Citation: Huang J, Han X, Wang X, et al. Single-Cell Profiling Reveals Divergent Mechanisms of Fibrosis in Localized Scleroderma and Systemic Sclerosis. Arthritis & Rheumatology. 2024. DOI: 10.1002/art.70039

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.